证券代码：300878 证券简称：维康药业 公告编号：2026-002 浙江维康药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日收到国家药品监督 管理局核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品的基本情况 生产企业：浙江维康药业股份有限公司 生产企业地址：浙江省丽水经济开发区遂松路 2 号 证书编号：2026S00186 药品批准文号：国药准字 C20260001 药品批准文号有效期：至 2031 年 01 月 19 日 药品名称：二冬汤颗粒 剂型：颗粒剂 规格：每袋相当于饮片 12.44g 注册分类：中药 3.1 类 上市许可持有人：浙江维康药业股份有限公司 上市许可持有人地址：浙江省丽水经济开发区遂松路 2 号 特此公告。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准本品上市，发给药品注册证书。质量标准、说明 书、标签及生产工艺照所附执行。本品上市后，应当继续完成以下工作：申请人 应履行主体责 ...

Investment Rating - The industry maintains an "Overweight" rating [9] Core Views - The report highlights the performance of the traditional Chinese medicine (TCM) sector, noting a 0.89% increase in the TCM II index, making it the second-best performing sub-sector in the pharmaceutical industry [3] - The report emphasizes the importance of the 2025 performance outlook and the progress of the essential drug catalog adjustments, with many companies showing positive profit growth [6] - The report suggests that the TCM industry may continue to experience structural differentiation, with companies focusing on external markets and innovation to find new growth points [6] Market Performance - The TCM II index closed at 6406.83 points, up 0.89% for the week, while the overall pharmaceutical index fell by 0.39% [3] - The best-performing companies in the TCM sector included *ST Changyao, ST Xiangxue, and Fangsheng Pharmaceutical, while the worst performers included Zhenbaodao and Pianzaihuang [3] Valuation - The TCM sector's PE (ttm) was 27.34X, up 0.23X week-on-week, with a PB (lf) of 2.3X, also showing a slight increase [4] - The PE is at the 28.89% percentile since 2013, while the PB is at the 5.74% percentile [4] Raw Material Market - The TCM raw material index rose by 1.1% due to increased demand for tonic herbs and price hikes in certain materials [5] - The overall market for TCM materials remains volatile, with a notable increase in demand for tonic herbs [5] Investment Suggestions - The report recommends focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [7] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and brands with strong market presence [13]

Core Insights - The Ministry of Agriculture and Rural Affairs has officially recognized Zhejiang Weikang Pharmaceutical Co., Ltd. as a national key laboratory, marking a significant milestone for the company and making it the first in Lishui City, Zhejiang Province to receive this designation [1][2]. Group 1: Company Achievements - Weikang Pharmaceutical has been acknowledged for its long-term commitment to technological innovation and modernization of traditional Chinese medicine [1]. - The company has established a diverse product system focusing on rapid-release dosage forms, including pills, dispersible tablets, soft capsules, and effervescent tablets, and has made significant advancements in quality standards, process optimization, and mechanism research [1]. - Weikang has formulated over 50 national standards and holds more than 40 national invention patents, receiving multiple honors such as National High-tech Enterprise and National Intellectual Property Demonstration Enterprise [1]. Group 2: Future Prospects - The newly approved national key laboratory will enhance Weikang's innovation in the modernization of traditional Chinese medicine and its integration with industry [2]. - The laboratory will focus on the development of innovative traditional Chinese medicines, improved new drugs, and classic formulas, aiming to promote the transformation of scientific achievements and cultivate high-level talent [2]. - Weikang aims to build a high-level research and development platform that integrates resource aggregation, technology leadership, and industry radiation, thereby enhancing its core competitiveness in the pharmaceutical sector [2].

Investment Rating - The industry maintains a "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [6]. Core Insights - The Chinese medicine sector experienced a decline of 1% last week, with the overall pharmaceutical and biological index down by 0.68%. The only sub-sector to record positive returns was medical services, which rose by 3.29% [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is currently at 27.11X, a decrease of 0.28X week-on-week, while the price-to-book (PB) ratio stands at 2.28X, down by 0.02X. These ratios indicate that the sector is within the 28.25% and 5.37% percentiles since 2013, respectively [3]. - The market for traditional Chinese medicine materials is experiencing reduced traffic, with a downward trend expected throughout 2025 due to supply expansion leading to a mismatch in supply and demand. The overall price index for traditional Chinese medicine materials fell by 29.31 points from the beginning to the end of 2025 [4]. - The adjustment of the essential drug list is anticipated to make significant progress in 2026, enhancing the accessibility of grassroots medications and potentially expanding the market rapidly [5]. Summary by Sections Market Performance - The Chinese medicine sector's index closed at 6350.32 points, reflecting a 1% decline last week. In comparison, the chemical pharmaceuticals and biological products sectors also saw declines of 2.4% and 1.21%, respectively [2][12]. Valuation - The current PE ratio for the Chinese medicine sector is 27.11X, with a year-high of 30.26X and a year-low of 24.72X. The PB ratio is 2.28X, with a maximum of 2.52X and a minimum of 2.17X over the past year [3]. Supply Chain Insights - The market for traditional Chinese medicine materials is currently facing a decrease in traffic, with a price index showing a downward trend. The overall price index for 2025 is expected to reflect a decline due to previous overproduction [4]. Policy Developments - The essential drug list has not been updated since 2018, but significant adjustments are expected in 2026, which may enhance the synergy between the essential drug list and medical insurance policies [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform. Companies with strong R&D capabilities and unique products are highlighted as potential investment opportunities [6][10].

证券之星消息，1月16日中药板块较上一交易日下跌0.59%，*ST长药领跌。当日上证指数报收于 4101.91，下跌0.26%。深证成指报收于14281.08，下跌0.18%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600671 | 天目药业 | 18.41 | 4.07% | 4.04万 | | 7418.12万 | | 002317 | 众生药业 | 22.10 | 3.32% | 86.21万 | | 18.54亿 | | 300878 | 维康药业 | 32.84 | 2.34% | 1 6.12万 | | 2.07亿 | | 002864 | 盘龙药业 | 36.60 | 1.86% | 8.27万 | | 2.97亿 | | 301331 | 恩威医药 | 28.96 | 1.79% | 1.86万 | | 5360.93万 | | 002107 | 沃华医药 | 7.49 | 1.49% | 23.71万 | | 1.78亿 | | ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The market performance of the traditional Chinese medicine (TCM) sector has shown a modest increase of 2.89%, which is the smallest among the pharmaceutical sub-sectors due to a lack of short-term catalysts and market style shifts [4][5] - The TCM sector's price-to-earnings (PE) ratio (ttm) is 27.39X, reflecting a 0.76X increase from the previous week, while the price-to-book (PB) ratio (lf) stands at 2.3X, up 0.06X [6] - The national health conference held in January 2026 indicates a positive outlook for the penetration rate of TCM services, suggesting a comprehensive development approach for TCM in various healthcare aspects [8] Summary by Sections Market Performance - The TCM sector's performance is lagging behind other pharmaceutical sub-sectors, with a 12-month relative return of -24% compared to the CSI 300 index [4] - The TCM sector's index closed at 6414.65 points, with a weekly increase of 2.89% [21] Valuation - The TCM sector's PE ratio (ttm) is at 27.39X, with a maximum of 30.26X and a minimum of 24.72X over the past year [6] - The PB ratio (lf) is 2.3X, with a maximum of 2.52X and a minimum of 2.17X in the same period [6] Industry Trends - The TCM material market has seen a slight decline in price index due to reduced market traffic, with a total index of 227.06 points, down 0.6% week-on-week [7] - The national health conference emphasizes the ongoing development of TCM services, which is expected to enhance its integration into the healthcare system [8] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [9] - Specific investment targets include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [11]

Market Performance - The A-share market showed significant strength with the Shanghai Composite Index rising by 0.92%, surpassing 4100 points, marking a new high in over 10 years [1] - For the week, the Shanghai Composite Index increased by 3.82%, the Shenzhen Component Index by 4.4%, and the ChiNext Index by 3.89% [1] Trading Volume - The total market turnover exceeded 3.15 trillion yuan, an increase of 326.1 billion yuan from the previous trading day, marking the sixth occurrence in history where turnover surpassed 3 trillion yuan [3] - Over 3900 stocks in the market experienced gains [3] AI Sector - The AI application sector saw a collective surge, with concepts like Xiaohongshu leading the gains, followed by Sora and Kuaishou [3][7] - The AI application sector is expected to enter a "golden year" in 2026, driven by technological maturity, supportive policies, and market demand [10][11] Notable Stocks - Zhite New Materials became the first stock to double in 2026, with a price increase of over 148% from January 5 to January 9, achieving five consecutive "20CM" limit-ups [3][4] - The stock is associated with AI-driven scientific research, new materials, robotics, and quantum technology [4][5] Innovation Drug Sector - The innovative drug sector experienced a strong rally, with companies like Weikang Pharmaceutical and Qianyan Bio hitting the "20CM" limit-up [13] - The National Medical Products Administration is optimizing the approval process for urgently needed foreign drugs, which is expected to support the innovative drug sector's growth [16][17]

Market Performance - The Chinese medicine sector rose by 0.63% on January 9, with Weikang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4120.43, up 0.92%, while the Shenzhen Component Index closed at 14120.15, up 1.15% [1] Top Gainers in Chinese Medicine Sector - Weikang Pharmaceutical (300878) closed at 35.33, with a significant increase of 20.01% and a trading volume of 68,800 shares, amounting to a transaction value of 231 million yuan [1] - Wanbangde (002082) saw a rise of 4.66%, closing at 15.05 with a trading volume of 195,600 shares [1] - Wohua Pharmaceutical (002107) increased by 3.23%, closing at 7.36 with a trading volume of 282,400 shares [1] Top Losers in Chinese Medicine Sector - ST Changyao (300391) experienced a decline of 6.90%, closing at 0.81 with a trading volume of 632,400 shares [2] - Enwei Pharmaceutical (301331) fell by 0.72%, closing at 28.85 with a trading volume of 18,300 shares [2] - Jiangzhong Pharmaceutical (600750) decreased by 0.65%, closing at 22.95 with a trading volume of 72,700 shares [2] Capital Flow Analysis - The Chinese medicine sector saw a net outflow of 95.72 million yuan from institutional investors, while retail investors contributed a net inflow of 171 million yuan [2] - Major stocks like Zhongsheng Pharmaceutical (002317) had a net inflow of 71.99 million yuan from institutional investors, despite a net outflow from retail investors [3] - Yunnan Baiyao (000538) also saw significant institutional inflow of 63.84 million yuan, while retail investors showed a net outflow [3]

Company Performance - The stock price of Aorite reached a historical high, increasing by 8.17% to 30.58 yuan, with a trading volume of 16.094 million shares and a transaction value of 470 million yuan, resulting in a turnover rate of 3.96% [2] - For the first three quarters, the company achieved an operating income of 1.237 billion yuan, representing a year-on-year growth of 13.67%, and a net profit of 354 million yuan, reflecting a year-on-year increase of 24.58% [2] - The basic earnings per share were reported at 0.8700 yuan, with a weighted average return on equity of 14.37% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which Aorite belongs, experienced an overall increase of 1.62%, with 413 stocks rising and 11 stocks, including Weikang Pharmaceutical and Dian Diagnostics, hitting the daily limit [2] - Conversely, 76 stocks in the industry saw declines, with the largest drops recorded by Meihua Medical, Aipeng Medical, and *ST Changyao, with declines of 10.52%, 8.26%, and 8.05% respectively [2]

Core Viewpoint - The pharmaceutical sector is experiencing significant stock price increases, with notable gains in several companies, indicating positive market sentiment and potential investment opportunities [1]. Group 1: Company Performance - Weikang Pharmaceutical has seen its stock price rise by over 15% [1]. - Frontline Bio and Shanghai Yizhong have both increased by over 10% [1]. - Other companies such as Lianhuan Pharmaceutical, Hongbo Pharmaceutical, Zhixiang Jintai, and Chengda Pharmaceutical are also experiencing upward trends in their stock prices [1].